help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. 1, 16-24, January 2008; doi:10.1634/theoncologist.2007-0199
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeuti...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, P. D.
Right arrow Articles by Goss, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, P. D.
Right arrow Articles by Goss, P. E.

Clinical Pharmacology

The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer

Paula D. Ryan, Paul E. Goss

Massachusetts General Hospital, Boston, Massachusetts, USA

Key Words. Insulin-like growth factor-I • Insulin-like growth factor-II • Insulin-like growth factor-I receptor Breast cancer • Review

Correspondence: Correspondence: Paula D. Ryan, M.D., Ph.D., Massachusetts General Hospital, LRH 308, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-5046; Fax: 617-643-0589; e-mail: pdryan{at}partners.org

Disclosure: P.E.G. has acted as a consultant to Novartis, AstraZeneca, and Pfizer, and P.D.R. has acted as a consultant to Pfizer, Genentech, and Novartis. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

The insulin-like growth factor signaling pathway is important in many human cancers based on data from experimental models as well as epidemiological studies. Important therapies targeted at this pathway have been or are being developed, including monoclonal antibodies to the insulin-like growth factor-I receptor and small molecule inhibitors of the tyrosine kinase function of this receptor. These investigational therapies are now being studied in clinical trials. Emerging data from phase I trials are encouraging regarding the safety of the monoclonal antibodies. In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2008 by AlphaMed Press.